Our leading subject matter experts share their insightful analysis and points of view to help you stay abreast of industry trends
This article was originally published in Drug Channels.
Over the past two decades, skyrocketing list prices for insulin have threatened medication adherence for the estimated 7.4 million American diabetics who rely on insulin to manage their disease. According to the American Diabetes Association, nearly one in four insulin-dependent diabetics have decreased or skipped doses because they could not afford to maintain their regimen.
With the passing of the Inflation Reduction Act of 2022, Congress addressed the financial strain on nearly three million diabetics…
This article was originally published in STAT.
For manufacturers, building a static commercialization strategy will only take you so far. But infusing that strategy with real-world data (RWD) — consisting of medical claims, lab testing and pharmacy data, and electronic health records — provides a more holistic view of the patient journey.
RWD fills in crucial missing puzzle pieces, especially when it’s integrated alongside payer coverage data. It can show if a patient is unable to access a drug and why — insights…
Respiratory syncytial virus (RSV) can impact anyone, but infants and older adults are most at risk of illness. With multiple new immunizing agents gaining FDA approval in 2023—and more in the pipeline—manufacturers and payers have a role to play in educating patients and providers about the importance of immunizations to combat RSV.
RSV, a contagious virus that can cause severe illness or death, is a common cause of respiratory illness. According to the U.S. Centers for Disease Control and Prevention (CDC),…
For manufacturers, the success of a new brand hinges on its uptake in the first few months after launch. Many pharma companies are surprised to realize that payer coverage is more limited than anticipated, especially in highly competitive markets. A poor launch can quickly lead to a disappointing performance trajectory.
To predict payer behavior with accuracy, many manufacturers analyze analogous market access scenarios to better anticipate the payer policies that might apply to their therapy. Analog analyses can reveal the details…
Ever since the Inflation Reduction Act (IRA) became law, pharma companies have struggled to identify how these changes will affect their business. In many ways, the IRA is forcing a marriage of necessity between product development and market access, as manufacturers must now be more focused on anticipating future market states for their potential and existing pipeline.
In our last IRA Q&A blog, we focused on the Medicare Drug Negotiation Program. Today, we’ll focus on the overall impact of the IRA,…
Since the passing of the Inflation Reduction Act (IRA) last fall, pharma companies have been bracing for the impact of its provisions. The main healthcare-related IRA policies are the out-of-pocket spending cap, the Medicare Drug Price Negotiation Program, and the penalty for increasing drug prices faster than inflation.
To get a better sense of what a post-IRA future might look like, we asked two MMIT experts to weigh in on the questions our clients are asking. In this blog, we’ll focus…
In the past few years, real-world data (RWD) has become an increasingly important element of a successful market access strategy. By blending claims and lab data with clinical pathway and payer coverage data, pharma companies can get full visibility into what’s happening in the market.
But how, exactly? What can a unified source of RWD reveal about the patient journey? And, most importantly, how can manufacturers use those insights to expand patient access to their therapies? The key to harnessing RWD…
Dallas Mavericks owner and venture capitalist Mark Cuban is taking aim at drug prices with his discount prescription drugs startup, Mark Cuban Cost Plus Drug Company. However, payers are divided on whether they want to work with the company, according to new MMIT research.
By leveraging direct sourcing, Cost Plus Drugs’ goal is to eliminate excessive markups on prescription drugs. Cost Plus’ online pharmacy sells directly to consumers, and the firm is registered as a pharmaceutical wholesaler with the FDA.
Coherus…
In an effort to lower the cost of specialty drugs, many payers have initiated site-of-care optimization strategies. By encouraging patients to receive therapies in more cost-effective settings — such as physician offices, infusion clinics, or at home — payers can reduce unnecessary expenses while ensuring members receive clinically appropriate care.
In addition to price concerns, medication compliance also plays a significant role in payers’ preference for a particular site of care. Payers obviously want their members to take their medications as…
Even though we knew it was coming, the end of the COVID public health emergency (PHE) on May 11, 2023, still took the healthcare industry by surprise. While the end of the PHE resulted in the rollback of many COVID-19 programs, it also changed the ways that Medicare patients can access oral therapies from community oncology clinics.
In September 2021, the Centers for Medicare and Medicaid Services (CMS) released an FAQ shifting the interpretation of the Stark Law. Though community practices…
